1. Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized phase II, placebo-controlled trial. Issue 7 (3rd July 2021) Authors: Park, Juliana; Archuleta, Sophia; Oh, May-Lin Helen; Shek, Lynette Pei-Chi; Wang, Hao; Bonaparte, Matthew; Frago, Carina; Bouckenooghe, Alain; Jantet-Blaudez, Frederique; Begue, Sarah; Gimenez-Fourage, Sophie; Pagnon, Anke Journal: Human vaccines & immunotherapeutics Issue: Volume 17:Issue 7(2021) Page Start: 2107 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗